Acutaas Chemicals enterprise value

Share price at each year-end

Tap a line for its trend	Currentlast 12M	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus


32,558	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
289	216	185	29.7	30.5
62.9	57.2	10.5	8.8	—
26.5	26.5	8.2	217	3.6
32,358	—	—	—	—
−262	−189	−177	187	−26.9
₹3,952.35	—	—	—	—

1,947	1,737	1,328	899	598
1.4%	1.5%	0.6%	24.1%	0.6%
0.00×	—	—	—	—

20.32×	—	—	—	—
51.92×	—	—	—	—
55.67×	—	—	—	—
1,593	1,339	1,007	717	617
623	480	232	128	123
581	444	205	112	110
—	292	118	125	65.5
−35.8	−35.8	−76.3	−155	−30.9
—	−36.1	−77.9	−158	−31.5
—	328	195	280	96.4

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ACUTAAS₹3,976.70

Acutaas Chemicals Ltd.

· Pharma & Health

₹ CrorePeersANURAS AETHER BLUEJET CAPLIPOINT CONCORDBIO EMCURE JBCHEPHARM ERISMcap ₹32,558 Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current/LTM TTM · last close
Market Capitalization	—	—	—	—	32,557.7
- Cash, Equiv & ST Investments	30.5	29.7	185.2	215.6	288.8
+ Minority Interest	—	8.8	10.5	57.2	62.9
+ Total Debt	3.6	216.6	8.2	26.5	26.5
Enterprise Value	—	—	—	—	32,358.4
Net Debt (memo)	-26.9	186.9	-177.0	-189.1	-262.3
EV per Share	—	—	—	—	3,952.35

Total Capital	597.6	899.4	1,328.3	1,737.2	1,946.9
Total Debt/Total Capital	0.60	24.09	0.62	1.52	1.36
Total Debt/EV	—	—	—	—	0.00

EV/Sales	—	—	—	—	20.32
EV/EBITDA	—	—	—	—	51.92
EV/EBIT	—	—	—	—	55.67
Reference Items — Trailing FY Values
Sales	616.7	717.5	1,006.9	1,339.4	1,592.5
EBITDA	122.6	128.5	232.1	480.4	623.2
EBIT	110.3	112.4	205.5	444.4	581.2
Operating Cash Flow	65.5	125.2	118.3	292.2	—
Free Cash Flow	-30.9	-155.2	-76.3	-35.8	-35.8
FCFF (free cash flow to the firm)	-31.5	-157.6	-77.9	-36.1	—
Capital Expenditure	96.4	280.4	194.6	328.0	—

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.